Abstract
Alterations of the ubiquitin proteasome system (UPS) contribute to the progression of many diseases, such as cancer, neurodegenerative diseases, immunological disorders, and inflammation. Pharmacologic inhibition of specific ubiquitin regulatory enzymes and ubiquitination events is an important challenge in drug discovery. Identifying the substrates of the various enzymes that participate in the UPS is needed to determine which enzymes are potential drug candidates. Additionally, identifying the ubiquitination events regulated by pharmacological drugs can potentially discover new applications. In this review we describe mass spectrometry-based proteomic approaches for the identification of ubiquitinated proteins and their modification sites on a proteome-wide scale, focusing on the ubiquitin remnant profiling, a newly developed ubiquitination profiling technique. We then discuss the application of this approach for the profiling of ubiquitination events regulated by cell signaling pathways and explore its future applications for drug discovery in the UPS.
Keywords: Ubiquitin proteasome system, ubiquitin remnant-containing peptide, ubiquitin remnant profiling, drug discovery, LC-MS/MS.
Current Pharmaceutical Design
Title:Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Volume: 19 Issue: 18
Author(s): Guoqiang Xu and Samie R. Jaffrey
Affiliation:
Keywords: Ubiquitin proteasome system, ubiquitin remnant-containing peptide, ubiquitin remnant profiling, drug discovery, LC-MS/MS.
Abstract: Alterations of the ubiquitin proteasome system (UPS) contribute to the progression of many diseases, such as cancer, neurodegenerative diseases, immunological disorders, and inflammation. Pharmacologic inhibition of specific ubiquitin regulatory enzymes and ubiquitination events is an important challenge in drug discovery. Identifying the substrates of the various enzymes that participate in the UPS is needed to determine which enzymes are potential drug candidates. Additionally, identifying the ubiquitination events regulated by pharmacological drugs can potentially discover new applications. In this review we describe mass spectrometry-based proteomic approaches for the identification of ubiquitinated proteins and their modification sites on a proteome-wide scale, focusing on the ubiquitin remnant profiling, a newly developed ubiquitination profiling technique. We then discuss the application of this approach for the profiling of ubiquitination events regulated by cell signaling pathways and explore its future applications for drug discovery in the UPS.
Export Options
About this article
Cite this article as:
Xu Guoqiang and Jaffrey Samie R., Comprehensive Profiling of Protein Ubiquitination for Drug Discovery, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/13816128113199990305
DOI https://dx.doi.org/10.2174/13816128113199990305 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis
Current Rheumatology Reviews Regulation of Tumor-Stromal Fibroblast Interactions: Implications in Anticancer Therapy
Current Medicinal Chemistry Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer: Update
Medicinal Chemistry Reviews - Online (Discontinued) mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Actual and Potential Agents and Biomarkers in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry 7-prenyloxi-6-methoxycoumarin from Polygala sabulosa A.W. Bennett Regulates p38 MAPK and NF-kB Pathways Inhibiting the Inflammation Induced by Carrageenan in the Mouse Model of Pleurisy
Inflammation & Allergy - Drug Targets (Discontinued) Noscapine-loaded PLA Nanoparticles: Systematic Study of Effect of Formulation and Process Variables on Particle Size, Drug Loading and Entrapment Efficiency
Pharmaceutical Nanotechnology Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Current Drug Metabolism Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Mini-Reviews in Medicinal Chemistry Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design Efficacy and Toxicological Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets